U.S. markets close in 5 hours 3 minutes

Evotec SE (EVT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
25.56+0.53 (+2.12%)
As of 10:32AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.03
Bid24.99 x 400000
Ask25.04 x 400000
Day's Range25.56 - 25.79
52 Week Range20.25 - 45.70
Avg. Volume2,166
Market Cap4.575B
Beta (5Y Monthly)0.98
PE Ratio (TTM)48.41
EPS (TTM)0.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EVT.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more

      Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

      (ALM), a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.

    • Benzinga

      Sernova, Evotec Join Forces To Develop 'Functional Cure' For Diabetes

      Sernova Corp and Evotec SE (NASDAQ: EVO) have announced an exclusive global strategic partnership to develop cell therapy treatment for insulin-dependent diabetes. The companies will leverage their respective technologies and scientific expertise to develop an implantable iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. The partnership provides Sernova a global exclusive option to license Evotec's iPSC-based beta cells to treat both type 1 and type 2 diabetes. Also Read

    • GlobeNewswire

      Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes

      Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta CellsPartners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent DiabetesEvotec to Make Strategic Equity Investment of CAD $27 M / €20 M in SernovaSernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022 LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/X